The Role of Nf-kB and Nrf2 Transcription Factors Inhibitors in Bronchial Asthma: A Case Report

Marco Umberto Scaramozzino^1,2*, Fabiana Furci³, Corrado Pelaia⁴ and Giovanni Sapone⁵

¹Director, Outpatient Clinic of Pulmonology “La Madonnina”, Italy
²Head of Interventional Pulmonology Villa Aurora Hospital, Reggio Calabria, Italy
³Section of Allergology, Provincial Healthcare Unit - Vibo Valentia, 89900, Italy
⁴Department of Health Sciences, University of Magna Graecia of Catanzaro, - Catanzaro, 88100, Italy
⁵Head Nurse, Cardiology Department, Madonna della Consolazione Polyclinic, Reggio Calabria, Italy

*Corresponding Author: Marco Umberto Scaramozzino, Director, Outpatient Clinic of Pulmonology, “La Madonnina” and Head of Interventional Pulmonology Villa Aurora Hospital, Via Villa Aurora n°25 89100 Reggio Calabria, Italy.

Received: December 16, 2025; Published: January 21, 2026

Abstract

Bronchial asthma is a chronic respiratory condition characterized by airway inflammation and bronchial hyperreactivity, influenced by genetic, environmental, and immunological factors. The pathogenesis involves chronic inflammation mediated by immune cells and pro-inflammatory cytokines, with critical roles played by the transcription factors Nf-kB and Nrf2. Omaveloxolone, an investigational drug for Friedreich's Ataxia, modulates the Nrf2 pathway and inhibits Nf-kB, potentially offering therapeutic benefits in asthma management. Preliminary studies suggest that Nrf2 activation may improve lung function and reduce inflammation in asthmatic patients, warranting further research to explore its efficacy and safety in this context.

 Keywords: Asthma; Pulmonology; NF-Kb; Nrf2; Trascription Factors; Ataxia; Inhibitors

References

1. Global Initiative for Asthma (GINA). “Global Strategy for Asthma Management and Prevention” (2024).
2. Holgate ST and Polosa R. “The mechanisms, pathophysiology, and management of severe asthma in adults”. The Lancet9643 (2008): 1017-1029.
3. Barnes PJ. “Th2 cytokines and asthma: an update”. Molecular Immunology6 (2010): 1230-1236.
4. Chen Z J and Sun L J. “Non-canonical NF-κB signaling pathway”. Cell Research1 (2016): 1-2.
5. Zhang D D. “Mechanistic studies of the Nrf2-Keap1 signaling pathway”. Drug Metabolism Reviews4 (2006): 769-789.
6. Koeppen A H and Mazurkiewicz J E. "Friedreich Ataxia: Pathophysiology and Treatment”. Current Treatment Options in Neurology5 (2013): 563-577.
7. Gonzalez-Fernandez C., et al. "Omaveloxolone in Friedreich Ataxia: A Review of the Evidence”. Neurology 12 (2021): e1640-e1650.
8. Miller J W., et al. "Nrf2 Activation as a Therapeutic Strategy for Neurodegenerative Diseases”. Frontiers in Neuroscience 14 (2020): 1-12.
9. Huang H C and Nguyen T. "Nrf2: A Key Regulator of Antioxidant Defenses”. Free Radical Biology and Medicine 8 (2000): 892-898.
10. Bousquet J., et al. "Asthma: A Global Perspective”. The Journal of Allergy and Clinical Immunology1 (2020): 1-12.

Citation

Citation: Marco Umberto Scaramozzino., et al. “The Role of Nf-kB and Nrf2 Transcription Factors Inhibitors in Bronchial Asthma: A Case Report”.Acta Scientific Medical Sciences 10.2 (2026): 48-51.

Copyright

Copyright: © 2026 Marco Umberto Scaramozzino., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.